SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

FDC to acquire ‘ENTEROPLUS’ from GlaxoSmithKline Pharmaceuticals

18 Oct 2019 Evaluate

FDC has entered into definitive documents (including a trademark assignment deed) on October 16, 2019 with GlaxoSmithKline Pharmaceuticals (GSK) for acquiring the registered Trademark ‘ENTEROPLUS’ from GSK. The Company would have acquired all the rights of this Trademark/Brand 'ENTEROPLUS'.

FDC is engaged in manufacture of specialized formulations, and oral rehydration salts (ORS).

FDC Share Price

431.65 10.95 (2.60%)
09-Jul-2026 15:33 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1938.00
Dr. Reddys Labs. 1270.60
Cipla 1443.00
Zydus Lifesciences 1161.40
Lupin 2504.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: